CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer

Thanyanan Reungwetwattana, Kazuhiko Nakagawa, Byoung Chul Cho, Manuel Cobo, Eun Kyung Cho, Alessandro Bertolini, Sabine Bohnet, Caicun Zhou, Ki Hyeong Lee, Naoyuki Nogami, Isamu Okamoto, Natasha Leighl, Rachel Hodge, Astrid McKeown, Andrew P. Brown, Yuri Rukazenkov, Suresh S. Ramalingam, Johan Vansteenkiste*

*Corresponding author for this work
134 Citations (Scopus)

Fingerprint

Dive into the research topics of 'CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences